BioNTech EPS beats by €1.33, beats on revenue

seekingalpha2021-05-10

(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

vSup_puSv
2021-05-11
vSup_puSv
Pls like & comments
- Kernsion:
  Done
Kel9670ong
2021-05-10
Kel9670ong
Nice
nctony
2021-05-10
nctony
Medication share is strong now[吃瓜]
wenz
2021-05-10
wenz
Comment
- 财务自由FIRE:
  ok
- CelineDang:
  reply comment
OWENLEECT
2021-05-10
OWENLEECT
Yeah.. 300
- CelineDang:
  reply comment
Money601
2021-05-10
Money601
?
- CelineDang:
  reply comment

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173680926?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-05-10 19:35","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1173680926","market":"us","top_or_hot":-1,"title":"BioNTech EPS beats by €1.33, beats on revenue","media":"seekingalpha","content":"<div>\n<p>(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update ...</p>\n\n<a href=\"https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech EPS beats by €1.33, beats on revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech EPS beats by €1.33, beats on revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 19:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update ...</p>\n\n<a href=\"https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue","article_id":"1173680926","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173680926","pubTimestamp":1620646501,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunother","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"BioNTech EPS超过预期1.33欧元,营收超过预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":0.9},"content_text":"(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended March 31, 2021.BioNTech(NASDAQ:BNTX): Q1 GAAP EPS of €4.39beats by €1.33.Revenue of €2.05B (+7300.7% Y/Y)beats by €270M.More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyondAnnounced planned expansion of global footprint toAsiawith establishment of first regional headquarters for south eastAsiainSingapore, including a fully-integrated and state-of-the art mRNA manufacturing facilityIn oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTech’s oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing trials.BioNTech rose more than 8% in premarket trading.First quarter 2021 financial results (unaudited)Revenues: Total revenues were estimated to be €2,048.4 million1for the three months ended March 31, 2021, compared to €27.7 million for the three months ended March 31, 2020. The increase was mainly due to rapidly increasing the supply of COVID-19 vaccine worldwide. Under the collaboration agreements, territories have been allocated between BioNTech, Pfizer and Fosun Pharma based on marketing and distribution rights. BioNTech’s commercial revenues include an estimated amount of €1,751.9 million1comprising BioNTech’s share of gross profit from COVID-19 vaccine sales in Pfizer’s territories, which represents a net figure, as well as sales milestones. In addition, €63.9 million sales to BioNTech’s collaboration partners of products manufactured by BioNTech and €199.8 million direct COVID-19 vaccine sales to customers in BioNTech’s territory have been recognized.Cost of Sales: Cost of sales were estimated to be €233.1 million1for the three months ended March 31, 2021, compared to €5.9 million for the three months ended March 31, 2020. Estimated cost of sales of €223.2 million1were recognized with respect to BioNTech’s COVID-19 vaccine sales and include Pfizer’s share of gross profits earned by BioNTech.Research and Development Expenses: Research and development expenses were €216.2 million for the three months ended March 31, 2021, compared to €65.1 million for the three months ended March 31, 2020. The increase was mainly due to an increase in research and development expenses for BioNTech’s BNT162 program, recorded as purchased services with respect to those expenses, which were initially incurred by Pfizer and subsequently charged to BioNTech under the collaboration agreement. The increase was further driven by an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements.General and Administrative Expenses: General and administrative expenses were €38.9 million for the three months ended March 31, 2021, compared to €15.8 million for the three months ended March 31, 2020. The increase was mainly due to higher expenses for professional services, an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements as well as higher insurance premiums.Income Taxes: Interim income taxes were €514.2 million for the first quarter of 2021 and were recognized using the estimated annual effective income tax rate of approximately 31%.Net Profit / (Loss): Net profit was €1,128.1 million for the three months ended March 31, 2021, compared to €53.4 million net loss for the three months ended March 31, 2020.Cash Position: Cash and cash equivalents as of March 31, 2021 were €891.5 million.Shares Outstanding: Shares outstanding as of March 31, 2021 were 241,521,065.Update on current signed COVID-19 vaccine order book:Estimated COVID-19 vaccine revenues to BioNTech upon delivery of currently signed supply contracts of ~1.8 billion doses is ~€12.4 billion.This revenue estimate reflects:Expected revenues from direct COVID-19 vaccine sales to customers in BioNTech’s territoryExpected revenues from sales to collaboration partners of products manufactured by BioNTechExpected sales milestone payments from collaboration partnersExpected revenues related to share of gross profit from COVID-19 vaccine sales in the collaboration partners’ territoriesAdditional revenues related to further supply contracts for deliveries in 2021 expected with first contracts in place for 2022 and beyond.Full year 2021 manufacturing capacity now targeting 3 billion doses and more than 3 billion doses for the year 2022.On Track with Previously Stated 2021 Financial Outlook:","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":199383590,"gmtCreate":1620685813010,"gmtModify":1704346554568,"author":{"id":"3581550492242446","authorId":"3581550492242446","name":"vSup_puSv","avatar":"https://static.tigerbbs.com/a1150421a148787160d999c5a94bed8e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581550492242446","authorIdStr":"3581550492242446"},"htmlText":"Pls like &amp; comments","listText":"Pls like &amp; comments","text":"Pls like & comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/199383590","repostId":1173680926,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4291379,"gmtCreate":1620729392117,"gmtModify":1680788114639,"authorId":3574200728285353,"author":{"id":3574200728285353,"idStr":"3574200728285353","authorId":3574200728285353,"name":"Kernsion","avatar":"https://static.tigerbbs.com/1ffac41f60c526771b9ca04ae229744f","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.13","exceedPercentage":"80.94%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":199383590,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":190777080,"gmtCreate":1620655235440,"gmtModify":1704346222416,"author":{"id":"3578468158955348","authorId":"3578468158955348","name":"Kel9670ong","avatar":"https://static.tigerbbs.com/bd86c42e207fbd94e7f8877a29457d71","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578468158955348","authorIdStr":"3578468158955348"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190777080","repostId":1173680926,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":190796545,"gmtCreate":1620650880987,"gmtModify":1704346106688,"author":{"id":"3557024931927052","authorId":"3557024931927052","name":"nctony","avatar":"https://static.tigerbbs.com/1449dfc5089ded0e8efe303fd4dd43b1","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3557024931927052","authorIdStr":"3557024931927052"},"htmlText":"Medication share is strong now[吃瓜]&nbsp;","listText":"Medication share is strong now[吃瓜]&nbsp;","text":"Medication share is strong now[吃瓜]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190796545","repostId":1173680926,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":190455899,"gmtCreate":1620647338911,"gmtModify":1704346054249,"author":{"id":"3581498879942189","authorId":"3581498879942189","name":"wenz","avatar":"https://static.tigerbbs.com/2ac1ff59f14d7f3731dc3d57955ca146","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581498879942189","authorIdStr":"3581498879942189"},"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/190455899","repostId":1173680926,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4280961,"gmtCreate":1620652092156,"gmtModify":1680787921946,"authorId":3572559338621373,"author":{"id":3572559338621373,"idStr":"3572559338621373","authorId":3572559338621373,"name":"财务自由FIRE","avatar":"https://community-static.tradeup.com/news/277d763b2c26eba668e9e0bf4c759ae2","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.30","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":190455899,"type":1,"supId":4280502,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":4280502,"gmtCreate":1620648077691,"gmtModify":1680787918273,"authorId":3582718916471703,"author":{"id":3582718916471703,"idStr":"3582718916471703","authorId":3582718916471703,"name":"CelineDang","avatar":"https://static.tigerbbs.com/8e51a48e7e0c121663678b012d37acb6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":190455899,"type":1,"supId":0,"prevId":0,"content":"reply comment","text":"reply comment","html":"reply comment"}],"langContent":"EN"},{"id":190458974,"gmtCreate":1620647004298,"gmtModify":1704346050164,"author":{"id":"3580620636230827","authorId":"3580620636230827","name":"OWENLEECT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3580620636230827","authorIdStr":"3580620636230827"},"htmlText":"Yeah.. 300","listText":"Yeah.. 300","text":"Yeah.. 300","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/190458974","repostId":1173680926,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4280505,"gmtCreate":1620648084955,"gmtModify":1680787917132,"authorId":3582718916471703,"author":{"id":3582718916471703,"idStr":"3582718916471703","authorId":3582718916471703,"name":"CelineDang","avatar":"https://static.tigerbbs.com/8e51a48e7e0c121663678b012d37acb6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":190458974,"type":1,"supId":0,"prevId":0,"content":"reply comment","text":"reply comment","html":"reply comment"}],"langContent":"EN"},{"id":190451788,"gmtCreate":1620646986144,"gmtModify":1704346049668,"author":{"id":"3582858901872554","authorId":"3582858901872554","name":"Money601","avatar":"https://static.tigerbbs.com/6b55bafa7547cf62c65d7bda1ee48b05","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582858901872554","authorIdStr":"3582858901872554"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/190451788","repostId":1173680926,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4280510,"gmtCreate":1620648109742,"gmtModify":1680787916543,"authorId":3582718916471703,"author":{"id":3582718916471703,"idStr":"3582718916471703","authorId":3582718916471703,"name":"CelineDang","avatar":"https://static.tigerbbs.com/8e51a48e7e0c121663678b012d37acb6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":190451788,"type":1,"supId":0,"prevId":0,"content":"reply comment","text":"reply comment","html":"reply comment"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":33,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173680926"}